Zydus Lifesciences has entered into a non-exclusive patent licensing agreement with Takeda Pharma to market the novel Potassium Competitive Acid Blocker (P-CAB) Vonoprazan in India, says a company statement. The drug will be marketed under the brand Vault.
Under the terms of this agreement, Zydus will be marketing the drug in India. Gastroesophageal Reflux Disease (GERD) is a prevalent condition affecting patients in India. The pooled prevalence of GERD in the Indian population is 15.6 % as per study published in Indian Journal of Gastroenterology, 2021, citing age, body mass index (BMI), diet, tea/coffee intake, tobacco, and alcohol consumption as risk factors.
Zydus already provides treatment options to manage GERD like Pantodac (Pantoprazole), Happi (Rabeprazole), and Ocid (Omeprazole).
A business journalist with around two decades of experience track...
Read MoreA business journalist with around two decades of experience tracking key consumer-focussed sectors like consumer durables, retail, consumer goods, aviation, automobiles and advertising, as well as economic ministries of the Union government. Now, writes primarily on pharmaceuticals and healthcare, and on issues of consumer interest. Besides also looks at trends that are shaping consumer behaviour and the broad consumer landscape. \nYou can follow Rupali on Twitter@Rupalijee.
Read Less
Start a Conversation
Post comment